Search
Tadalafil
go.drugbank.com/drugs/DB00820ApprovedInvestigational[L39100, L39105] It was first approved in 2003 by the FDA for use in ED and later in 2009 for PAH. … In contrast to other PDE5 inhibitors like [sildenafil], tadalafil has greater selectivity for PDE5 and a longer half-life which has made it a more suitable option for chronic once-daily dosing in the treatment
Categories: Antihypertensives for Pulmonary Arterial HypertensionProducts: LUDIKA TABLETAS RECUBIERTAS POR 20 MGOlutasidenib
go.drugbank.com/drugs/DB16267ApprovedInvestigational[L44256,L44261] It is indicated for the treatment of relapsed or refractory acute myeloid leukemia (AML) in patients with a susceptible IDH1 mutation as determined by an FDA-approved test. … [L44256] IDH1 mutations are common in different types of cancer, such as gliomas, AML, intrahepatic cholangiocarcinoma, chondrosarcoma, and myelodysplastic syndromes (MDS), and they lead to an increase
Helminth Infection
go.drugbank.com/conditions/DBCOND0082009Synonyms: Infection due to Class Cestoda and/or Class Trematoda and/or Phylum NemataSodium iodide
go.drugbank.com/drugs/DB11119ApprovedInvestigationalSodium iodide is a source of iodine and can be administered as a supplement for total parenteral nutrition [L2065] but is more commonly used in veterinary medicine. … Radiolabelled compound, [DB09293], is used as a diagnostic tool to evaluate thyroid function and morphology.
Mixtures: Micro+ Te PediatricRilpivirine
go.drugbank.com/drugs/DB08864ApprovedInvestigational[L31193] While previously administered once-monthly only, this combination product was granted FDA approval for dosing every two months on February 01, 2022 [L40084] and without the need for an oral lead-in … [L1030] On November 21, 2017, Rilpivirine, in combination with [dolutegravir], was approved as part of the first complete treatment regimen with only two drugs for the treatment of adults with HIV-1 named
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseSotorasib
go.drugbank.com/drugs/DB15569ApprovedInvestigational[A187547] The drug [MRTX849] is also currently being developed and has the same target. … [A187550] Mutant KRAS discovered in 1982 but was not considered a druggable target until the mid-2010s.[A235168] It is the first experimental KRAS inhibitor.
Omega-3-carboxylic acids
go.drugbank.com/drugs/DB09568ApprovedWithdrawnThe increased bioavailability is explained because OM3-CA is found in a form of polyunsaturated free fatty acids as opposed to other products whose form is as ethyl esters. … [A25808] It was developed by AstraZeneca Pharmaceuticals and firstly approved by the FDA on May 05, 2014.[L2386]
Procaine
go.drugbank.com/drugs/DB00721ApprovedInvestigationalVet approvedIt is mainly used for infiltration anesthesia, peripheral nerve block, and spinal block. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1016).
Mixtures: Sterile Concentrate For Cardioplegia InfusionCategories: Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use, Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeChloramphenicol
go.drugbank.com/drugs/DB00446ApprovedInvestigationalVet approvedWithdrawnIt has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. … An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically.
Mixtures: CLOXONA-OCategories: Antibiotics for Topical Use, Antibacterials for Systemic UsePlozasiran
go.drugbank.com/drugs/DB18997ApprovedInvestigational[L45864] Plozasiran was first approved by the FDA on November 18th, 2025, to reduce triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS).[L54603] … Plozasiran contains a covalently linked ligand containing three N-acetylgalactosamine (GalNAc) residues to facilitate delivery to hepatocytes where it works to reduce triglyceride levels.